HippoFi, Inc. announced its newest biologic product, PURbridge. This new form of active bioglass expands the already extensive portfolio of HippoFi's division of Regenerative Therapeutics, which continues to target a total Spine market, anticipated to reach $18 billion in 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.03 USD | +3.09% | -12.79% | +9.49% |
- Stock Market
- Equities
- ORHB Stock
- News ORHub, Inc.
- HippoFi, Inc.’s Regenerative Therapeutics Division, Launches PURbridge(TM) for Spine Surgery